<div dir="ltr">Here's another example of how you cannot predict what the COVID19 epidemic needs:<br><br><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)">>There seems to be quite a lot of literature that cationic surfaces (polymeric or inorganics) are good to deal with viruses. Folks have seen this with several materials with a high isoelectric point (Al, ZrO2..) and in solution with polyinorganic Al complexes. I know you are interested in using nanostructures in this context.. could you use nano materials that are cationic? Similarly.. nanomaterials can also be effective in enhancing UV generated radicals/singlet oxygen.. Hence a nanostructured surface of the right material with UV light, might be able to combine all these approaches in one system?</span><br><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)"><br></span></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)">PMR> This will have almost zero overlap with the Elsevier Coronavirus Hub but it's just as important.
<br></span></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)">Taylor and Francis: "nanomaterials", 85% PAYWALLED
Wiley: 19/20 top hits , i.e. 95% PAYWALLED
Sage: 16/20 top hits i.e. 80% PAYWALLED
Publishers. Your paywalls are massively destroying the research effort. CORD-19 is irrelevant. If you do not respond NOW the world will judge you vey harshly.
Librarians, Purchase Officers. Why continue to pay subscriptions to these companies? Its primary effect is to stop citizens having access to critical knowledge.</span></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)"><br></span></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap;background-color:rgb(248,248,248)">P.
</span></div></div><br><div class="gmail_quote"><div dir="ltr" class="gmail_attr">On Wed, Apr 1, 2020 at 10:43 AM Peter Murray-Rust <<a href="mailto:pm286@cam.ac.uk">pm286@cam.ac.uk</a>> wrote:<br></div><blockquote class="gmail_quote" style="margin:0px 0px 0px 0.8ex;border-left:1px solid rgb(204,204,204);padding-left:1ex"><div dir="ltr"><div dir="ltr"><br></div><br><div class="gmail_quote"><div dir="ltr" class="gmail_attr">On Wed, Apr 1, 2020 at 6:34 AM Thomas Krichel <<a href="mailto:krichel@openlib.org" target="_blank">krichel@openlib.org</a>> wrote:<br></div><blockquote class="gmail_quote" style="margin:0px 0px 0px 0.8ex;border-left:1px solid rgb(204,204,204);padding-left:1ex"> <a href="mailto:brentier@uliege.be" target="_blank">brentier@uliege.be</a> writes<br>
<br> In practice, I doubt that access to current research is such a big<br>
issue "NOW" as libraries and open access advocates make it appear to<br>
be. The average academic only reads about one hour a week. In most<br>
cases, if you know that a paper exist and who the author is, you can<br>
contact the author to get the paper. Most authors will comply because<br>
they crave citations. The open access situation will improve anyway<br>
as the virus crises in the long run will leave institutions too weak<br>
to afford the journal subscription folly. <br clear="all"><br></blockquote><div>The idea that readers want a single paper is absolutely out of date in the digital century. I want all information on "face mask"s - it's been requested by a Cambridge colleague. </div><div><br></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap">>We need urgent expert help for two respiratory surgeons looking for evidence of mask effectiveness for typical procedures (collecting samples, intubation, and on to more invasive procedures). Happy to put experts in touch with them quickly. Evidence based, ideally peer reviewed rather than opinion. Thank you.
</span></div><div><span style="color:rgb(29,28,29);font-family:Slack-Lato,appleLogo,sans-serif;font-size:15px;font-variant-ligatures:common-ligatures;white-space:pre-wrap"><br></span></div><div>Our system getpapers+AMI downloaded and analysed over 300 papers for this query in 5 minutes. See <a href="https://github.com/petermr/openVirus/blob/master/examples/n95/OVERVIEW.md" target="_blank">https://github.com/petermr/openVirus/blob/master/examples/n95/OVERVIEW.md</a> and <a href="https://github.com/petermr/openVirus/blob/master/examples/n95" target="_blank">https://github.com/petermr/openVirus/blob/master/examples/n95</a> for the actual papers. Anyone can do this on their laptop. For free. (If anyone says "what about Copyright"? I'll raise the ghost of Queen Anne and her wrath. Copyright has no place in modern science/medicine).Except they won't get most of the relevant papers from Springer, Elsevier, T+F, Wiley, Sage, JSTOR, as my software does not go behind paywalls.</div><div><br></div><div><br></div><div>It's more than that. Suppose I want all drugs related to chloroquine. The hydroxy derivative is called Plaquenil. I didn't know that. But the software developed by my group in Cambridge DOES know that. So we need to build an index of the chemistry in the literature.</div><div>If we do that we'll have a lawyer's letter from Elsevier or Wiley in 5 minutes and have my university banning me from Knowledge research, (Don't think it doesn't happen - it does - see <a href="https://www.slideshare.net/petermurrayrust/disrupting-the-publisheracademic-complex" target="_blank">https://www.slideshare.net/petermurrayrust/disrupting-the-publisheracademic-complex</a> for what they did to Chris Hartgerink , a PhD researcher at Tilburg, working on reproducible research. And I have other anecdotal evidence which I can't share.) .<br><br>Again,<br>Don't dictate what we want. Let us search the whole literature freely. Then we may need a new generation of publisher tools. And if you publishers actually have something to offer it will be decided on merit, not lawyers. <br><br>P.</div><div><br></div></div><br>-- <br><div dir="ltr"><div dir="ltr"><div><div dir="ltr"><div>"I always retain copyright in my papers, and nothing in any contract I sign with any publisher will override that fact. You should do the same".<br></div><div><br></div><div>Peter Murray-Rust<br>Reader Emeritus in Molecular Informatics<br>Unilever Centre, Dept. Of Chemistry<br>University of Cambridge<br>CB2 1EW, UK<br>+44-1223-763069</div></div></div></div></div></div>
</blockquote></div><br clear="all"><div><br></div>-- <br><div dir="ltr" class="gmail_signature"><div dir="ltr"><div><div dir="ltr"><div>"I always retain copyright in my papers, and nothing in any contract I sign with any publisher will override that fact. You should do the same".<br></div><div><br></div><div>Peter Murray-Rust<br>Reader Emeritus in Molecular Informatics<br>Unilever Centre, Dept. Of Chemistry<br>University of Cambridge<br>CB2 1EW, UK<br>+44-1223-763069</div></div></div></div></div>